By ROBERT CYRAN
The drug maker revealed accounting issues, a search for a new chief executive and new board seats as it struggles with debt and a falling stock price.
Published: March 22, 2016 at 12:00AM
from NYT Business Day http://ift.tt/1RfPfSr
from WordPress http://ift.tt/25gggOV
via Hadi Aboukhater
No comments:
Post a Comment